@karlilynnb1's double chin GLP-1 claims, fact-checked
Quick answer
The video implicitly attributes submental fat reduction to GLP-1 receptor agonist use. Large-scale trials including STEP 1 (Wilding et al., 2021) and SURMOUNT-1 (Jastreboff et al., 2022) confirm significant total body fat reduction with semaglutide and tirzepatide respectively, which physiologically explains facial fat changes. No clinical evidence isolates submental fat as a targeted outcome of GLP-1 therapy, and facial volume loss from rapid weight reduction carries its own documented cosmetic and dermatological considerations.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @karlilynnb1 actually say?
Honestly? Almost nothing, in words. The transcript is song lyrics, not a health claim. But the video does the talking for her: the caption reads "I don't know a life without a double chin… now it's just gone!!!" paired with the #glp1 hashtag. That pairing is the claim. She's attributing a visible change in submental fat, the fat under the chin, to GLP-1 receptor agonist use. She doesn't name a drug, doesn't discuss dosing, and doesn't say how long it took. The message is purely visual and emotional: GLP-1 changed my face. That's a real claim, even if no one said it out loud.
Before-and-after content like this is enormously influential precisely because it feels like proof without requiring any argument. Forty thousand views means forty thousand people who saw a result, not an explanation.
Does the science back this up?
Partially, yes. GLP-1 receptor agonists do reduce overall body fat, and facial and submental fat loss is a documented side effect, though not always a welcome one. The mechanism is systemic, not targeted. You cannot spot-reduce fat with a GLP-1, but when total fat mass drops significantly, the face often changes noticeably.
Semaglutide trials have shown meaningful reductions in body weight. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found a mean 14.9% body weight reduction over 68 weeks in adults with obesity. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 20.9% reduction in the highest-dose group. At those levels of weight loss, facial fat changes are plausible and expected. There is no dedicated randomized trial on submental fat and GLP-1 agents specifically, but the physiology is consistent with what she's showing.
What did they get wrong (or right)?
She didn't get anything factually wrong, because she didn't make a factual statement. That's actually the smarter move from a liability standpoint, but it creates a different problem: implication without accountability. The video implies GLP-1 is the reason for the change, with zero context about diet, exercise, starting weight, duration, or which drug she used. The #workoutmotivation hashtag is also there, which quietly suggests exercise may have played a role, but the #glp1 tag gets top billing in the caption.
What she got right is that visible fat loss around the face and jaw is a real and common outcome for people who lose substantial weight on GLP-1 therapy. That part is supported by the literature. What's missing is that this result is not guaranteed, not fast, and comes with real side effects that no 15-second before-after addresses. Nausea, muscle loss, and what clinicians now call "Ozempic face", meaning hollowed cheeks and accelerated facial aging, are documented concerns (Kahn et al., 2023, JAMA Dermatology).
What should you actually know?
GLP-1 drugs can absolutely change the way your face looks, but the change is a byproduct of systemic fat loss, not a cosmetic feature of the medication. Results vary enormously based on starting body composition, which drug is used, dose titration, and duration of treatment. The double chin disappearing is a realistic outcome for some people who lose 15-20% of their body weight on these agents. It is not a guaranteed outcome, and it is not the same as a cosmetic procedure that targets submental fat specifically.
There is also the issue of facial aging. Rapid fat loss in the face can cause skin laxity and volume loss that some patients find distressing. This is not a reason to avoid GLP-1 therapy if it's clinically indicated, but it is a reason to have a real conversation with a prescriber rather than making decisions based on a TikTok caption.
- GLP-1 therapy requires a licensed prescriber and an appropriate clinical indication.
- Compounded semaglutide is not equivalent to FDA-approved branded formulations.
- Weight loss results in trials are averages across populations, not guarantees for individuals.
The bottom line
This video isn't misinformation. It's an honest personal result shared without context. The danger isn't in what she said. It's in what 39,400 viewers will conclude without ever hearing about side effects, eligibility criteria, or what "gone" actually required in terms of time, drug, and lifestyle. Social proof is powerful, and before-after content on GLP-1 is currently running far ahead of the clinical conversations people need to have before starting treatment.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @karlilynnb1's double chin GLP-1 claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@karlilynnb1's double chin GLP-1 claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The video implicitly attributes submental fat reduction to GLP-1 receptor agonist use.
FormBlends verdict
The video implicitly attributes submental fat reduction to GLP-1 receptor agonist use. Large-scale trials including STEP 1 (Wilding et al., 2021) and SURMOUNT-1 (Jastreboff et al., 2022) confirm significant total body fat reduction with semaglutide and tirzepatide respectively, which physiologically explains facial fat changes. No clinical evidence isolates submental fat as a targeted outcome of GLP-1 therapy, and facial volume loss from rapid weight reduction carries its own documented cosmetic and dermatological considerations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video implicitly attributes submental fat reduction to GLP-1 receptor agonist use. Large-scale trials including STEP 1 (Wilding et al., 2021) and SURMOUNT-1 (Jastreboff et al., 2022) confirm significant total body fat reduction with semaglutide and tirzepatide respectively, which physiologically explains facial fat changes. No clinical evidence isolates submental fat as a targeted outcome of GLP-1 therapy, and facial volume loss from rapid weight reduction carries its own documented cosmetic and dermatological considerations.
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide produced a mean 14.9% body weight loss over 68 weeks, enough to plausibly alter facial fat distribution in many patients.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at highest dose produced up to 20.9% weight reduction, the largest recorded in a phase 3 GLP-1 trial to date.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide produced a mean 14.9% body weight loss over 68 weeks, enough to plausibly alter facial fat distribution in many patients.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at highest dose produced up to 20.9% weight reduction, the largest recorded in a phase 3 GLP-1 trial to date.
- GLP-1 drugs do not target submental fat specifically. Any facial change is a downstream effect of systemic fat loss, not a cosmetic mechanism of the drug.
- Rapid facial fat loss on GLP-1 therapy can cause skin laxity and volume loss. Kahn et al. (2023, JAMA Dermatology) documented this phenomenon, now commonly called 'Ozempic face.'
- Before-and-after content omits timeline, drug identity, dose, and lifestyle factors. Individual results depend on all of these variables and cannot be predicted from social media outcomes.
- Compounded GLP-1 formulations are not FDA-approved and are not clinically equivalent to brand-name drugs like Wegovy or Zepbound. A licensed prescriber must evaluate clinical appropriateness before any GLP-1 therapy is started.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Karli - Wellness Journey · TikTok creator
39.4K views on this video
I don’t know a life without a double chin… now it’s just gone!!! #fyp #sahm #wellnessjourney #glp1 #workoutmotivation
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Karli - Wellness Journey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.